Valuation: Gabather AB

Market Cap 21.61M 2.28M 1.97M 1.84M 1.69M 3.18M 217M 3.23M 8.47M 109M 8.56M 8.38M 363M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 18.47M 1.95M 1.69M 1.57M 1.44M 2.72M 186M 2.76M 7.24M 92.93M 7.32M 7.16M 310M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
88.76%
Yield 2024 *
-
Yield 2025 -
1 day-0.56%
1 week+11.32%
Current month+18.79%
1 month+2.91%
3 months-15.31%
6 months+18.00%
Current year+29.20%
1 week 0.03
Extreme 0.0276
0.04
1 month 0.03
Extreme 0.0262
0.04
Current year 0.02
Extreme 0.023
0.1
1 year 0.02
Extreme 0.023
0.1
3 years 0.02
Extreme 0.023
4.2
5 years 0.02
Extreme 0.023
6.79
10 years 0.02
Extreme 0.023
65.6
Manager TitleAgeSince
Chief Executive Officer - 2018-09-30
Chief Operating Officer - 2017-12-31
Chief Tech/Sci/R&D Officer - 2017-12-31
Director TitleAgeSince
Director/Board Member - 2014-08-31
Director/Board Member 60 2014-11-02
Chairman - 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%+11.32%-43.99%-98.69% 2.29M
+8.49%+23.38%+65.44%+104.90% 62.92B
+1.25%+2.22%+31.00%+70.51% 54.32B
+2.72%+0.88%-15.84%-12.03% 22.91B
-1.09%+29.18%+17.83%+496.18% 28.73B
+10.83%+21.32%+45.03%+2.02% 21.65B
+6.50%+8.41%+45.17%-21.02% 17.76B
-3.88%+20.98%+201.07%+350.94% 16.47B
+6.20%+12.16%+28.51%+629.05% 15.48B
+3.58%-3.39%+43.38%+166.75% 13.12B
Average +3.40%+7.88%+41.76%+168.86% 25.34B
Weighted average by Cap. +4.19%+9.95%+47.56%+164.92%

Financials

2024 2025
Net sales - -
Net income -7.75M -818K -708K -661K -606K -1.14M -77.89M -1.16M -3.04M -39.01M -3.07M -3.01M -130M -4.65M -491K -425K -396K -364K -684K -46.74M -695K -1.82M -23.41M -1.84M -1.8M -78.07M
Net Debt -878K -92.66K -80.14K -74.83K -68.66K -129K -8.82M -131K -344K -4.42M -348K -340K -14.73M -3.14M -332K -287K -268K -246K -462K -31.58M -469K -1.23M -15.82M -1.25M -1.22M -52.74M
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
26-08-07 SEK 0.0354 -0.56% 5,216,879
26-08-06 SEK 0.0356 +7.88% 3,689,995
26-08-05 SEK 0.0330 -3.51% 7,678,669
26-08-04 SEK 0.0342 +22.14% 7,359,816
26-08-03 SEK 0.0280 -6.04% 1,136,529
  1. Stock Market
  2. Stocks
  3. GABA Stock